EMA's Policy On Proactive Publication Of Clinical Data: First Reports To Be Made Public In Mid-Sept
This article was originally published in SRA
Executive Summary
The European Medicines Agency's policy on proactive publication of clinical trial data from drug applications submitted for approval after January 2015 is expected to result in the first clinical study reports being made public in mid-September. The EMA was earlier aiming to publish the clinical study reports under the policy from mid-20161.
You may also be interested in...
EMA Appeals Interim EU Court Orders Preventing Access To Documents
The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.